EyePoint Pharmaceuticals, Inc. Common Stock
Symbol: EYPT (NASDAQ)
14.26
▲ (1.46%) 0.205
Company Description:
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Key Stats
- Today's Open: $14.02
- Today's High: $14.895
- Today's Low: $13.67
- Today's Volume: 1.62M
- Yesterday Close: $14.05
- Yesterday High: $14.13
- Yesterday Low: $13.41
- Yesterday Volume: 759.69K
- Last Min Volume: 314
- Last Min High: $14.263
- Last Min Low: $14.251
- Last Min VWAP: $14.25877
Company Profile
- Name: EyePoint Pharmaceuticals, Inc. Common Stock
- Website: https://www.eyepointpharma.com
- Listed Date: 2005-01-27
- Location: WATERTOWN, MA
- Market Status: Active
- CIK Number: 0001314102
- SIC Code: 3826
- SIC description: LABORATORY ANALYTICAL INSTRUMENTS
- Market Cap: $968.43M
- Round Lot: 100
- Outstanding Shares: 68.93M
- Asset Type: CS
RECENT FILINGS FOR EYPT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-22 | 4 | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-07 | S-8 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-29 | 8-K/A | View |
| 2025-07-29 | 8-K | View |
| 2025-07-11 | 4 | View |
| 2025-07-11 | 4 | View |
| 2025-07-11 | 4 | View |
| 2025-07-08 | SCHEDULE 13G/A | View |
| 2025-07-02 | 4 | View |
| 2025-06-25 | 4 | View |
| 2025-06-20 | 8-K | View |
| 2025-05-27 | 4 | View |
| 2025-05-27 | 8-K | View |
| 2025-05-19 | 4 | View |
| 2025-05-15 | 4 | View |
| 2025-05-09 | DEFA14A | View |
| 2025-05-08 | 10-Q | View |
Latest News on EYPT